English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The World Health Organization International Classification of Diseases (2008) recognizes more than 50 types of lymphoma based on histopathological, immunohistochemical, cytogenetic and molecular analysis.1 Many lymphomas are potentially curable when treated with chemotherapy alone or in combination with radiotherapy, as well as with stem cell transplant.2,3 The Ann Arbor staging system applies to both Hodgkin’s and non-Hodgkin lymphoma.4,5 Staging with this system is based on the extension of lymph node groups involvement.6,7 The treatment of lymphoma depends on subtype and clinical stage. The therapeutic goal in Hodgkin’s and non-Hodgkin lymphoma is total cure of the disease.8,9 Cure can be achieved with chemotherapy, radiation therapy or combined immunotherapy.10 Computed tomography (CT) performed with 5-mm slices in multiplanar images is an appropriate method to assess treatment response according to the Response Criteria in Solid Tumors (RECIST) 1.1, based on unidimensional measurements with a pre-treatment baseline examination that should record two to five malignant lesions, representative of tumor burden, and that will be assessed in subsequent follow-up examinations. To classify a lymph node lesion as “target”, its diameter should be larger than 15 mm in its short axis. Any additional non-measurable lesion (< 10 or < 15 mm, pleural effusion, etc.) is recorded as a non-target lesion and is qualitatively Abstract

CT and 18-FDG PET/CT for the assessment of treatment response in Hodgkin’s and Non-Hodgkin lymphoma